Changes in periprosthetic bone mineral density and bone turnover markers after osseointegrated implant surgery: A cohort study of 20 transfemoral amputees with 30-month follow-up.


Journal

Prosthetics and orthotics international
ISSN: 1746-1553
Titre abrégé: Prosthet Orthot Int
Pays: France
ID NLM: 7707720

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 7 8 2019
medline: 25 2 2020
entrez: 7 8 2019
Statut: ppublish

Résumé

The osseointegrated implant system is a treatment option for people with transfemoral amputation, but implant removal is not uncommon. The association between bone mineral density changes or bone turnover markers and the need for implant removal has not previously been investigated. The aim was to evaluate changes in bone mineral density and bone turnover markers in people with transfemoral amputations treated with osseointegrated implants. This is a prospective cohort study. Nineteen patients were followed up for 30 months or until implant removal. Bone mineral density was measured in the lumbar spine, proximal femur and seven periprosthetic regions. 25-hydroxyvitamin (D2 + D3), parathyroid hormone, N-terminal propeptide of type-I procollagen, C-telopeptide of type-I collagen, bone-specific alkaline phosphatase and osteocalcin were measured in blood samples. Four fixtures and three abutments were removed. Patients with removed implants had a decreased bone mineral density in the seven periprosthetic regions between 27% (95% confidence interval = 6; 43) and 38% (95% confidence interval = 19; 52) at 30-month follow-up compared to baseline ( Implant removal was associated with loss of periprosthetic bone mineral density and increase in C-telopeptide of type-I collagen in the years following osseointegrated surgery. This study offers new insight into changes in bone mineral density and bone turnover markers that precipitate aseptic or septic osseointegrated implant removal. Results of this study could contribute to clinical guidelines for monitoring rehabilitation progress and implant removal through dual-energy X-ray absorptiometry or surrogate markers like C-telopeptide of type-I collagen.

Sections du résumé

BACKGROUND BACKGROUND
The osseointegrated implant system is a treatment option for people with transfemoral amputation, but implant removal is not uncommon. The association between bone mineral density changes or bone turnover markers and the need for implant removal has not previously been investigated.
OBJECTIVES OBJECTIVE
The aim was to evaluate changes in bone mineral density and bone turnover markers in people with transfemoral amputations treated with osseointegrated implants.
STUDY DESIGN METHODS
This is a prospective cohort study.
METHODS METHODS
Nineteen patients were followed up for 30 months or until implant removal. Bone mineral density was measured in the lumbar spine, proximal femur and seven periprosthetic regions. 25-hydroxyvitamin (D2 + D3), parathyroid hormone, N-terminal propeptide of type-I procollagen, C-telopeptide of type-I collagen, bone-specific alkaline phosphatase and osteocalcin were measured in blood samples.
RESULTS RESULTS
Four fixtures and three abutments were removed. Patients with removed implants had a decreased bone mineral density in the seven periprosthetic regions between 27% (95% confidence interval = 6; 43) and 38% (95% confidence interval = 19; 52) at 30-month follow-up compared to baseline (
CONCLUSION CONCLUSIONS
Implant removal was associated with loss of periprosthetic bone mineral density and increase in C-telopeptide of type-I collagen in the years following osseointegrated surgery.
CLINICAL RELEVANCE CONCLUSIONS
This study offers new insight into changes in bone mineral density and bone turnover markers that precipitate aseptic or septic osseointegrated implant removal. Results of this study could contribute to clinical guidelines for monitoring rehabilitation progress and implant removal through dual-energy X-ray absorptiometry or surrogate markers like C-telopeptide of type-I collagen.

Identifiants

pubmed: 31385557
doi: 10.1177/0309364619866599
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-518

Auteurs

Rehne Lessmann Hansen (RL)

Orthopedic Research Unit, Aarhus University Hospital, Aarhus, Denmark.
Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.

Bente Lomholt Langdahl (BL)

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

Peter Holmberg Jørgensen (PH)

Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.

Klaus Kjær Petersen (KK)

Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.

Kjeld Søballe (K)

Orthopedic Research Unit, Aarhus University Hospital, Aarhus, Denmark.
Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University and INCUBA Skejby, Aarhus, Denmark.

Maiken Stilling (M)

Orthopedic Research Unit, Aarhus University Hospital, Aarhus, Denmark.
Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University and INCUBA Skejby, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH